📢 Stocks Trending NOW: #FFAI #MGRX #UGRO #ANNA #DKNG #TOVX #WRD #GMEX #SNPS #VST

Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales - - Cash and cash equivalents of

#TOVX Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

www.stocktitan.net/news/TOVX/theriva-tm-bio...

#TOVX #TherivaBiologics #StockMarket #BiotechStocks #TechnicalAnalysis #Investing #AMEX #SmallCap #StockAnalysis #RSI #MACD #StockForecasting #HealthStocks #BiologicalTreatments #DayTrading #FinanceNews #HoldRating #MarketIndicators #StockUpdate #InvestmentStrategy youtu.be/wbPdAXT_ofw

📢 Stocks Trending NOW: #DBRG #SOPA #FTEL #BNAI #RPGL #TOVX #BSLK #MASK #PRAX #SFTBF

Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results Theriva Biologics (NYSE: TOVX) reported Q3 2025 operational and financial results with key clinical updates and cash guidance. Expanded VIRAGE Phase 2b data for VCN-01 in metastatic PDAC showed the study met primary endpoints with improved OS, PFS and DoR, measurable viral genomes for ≥3 months, and greater benefit with two doses.Preclinical data for next‑gen VCN-12 showed higher tumor killing and hyaluronidase activity versus VCN-01. Cash was $7.5M at Sept 30, 2025 and increased to $15.5M by Nov 10, 2025, funding operations into Q1 2027.

#TOVX Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results

www.stocktitan.net/news/TOVX/theriva-tm-bio...

Theriva Biologics Provides Response to Unusual Market Action Theriva Biologics (NYSE American: TOVX) announced awareness of unusual trading activity in its common stock on the NYSE American on October 24, 2025. The company said it has made inquiries, does not believe corrective actions are appropriate, and is not aware of any material development in its business or affairs that would explain the trading.The company noted a prior announcement on October 13, 2025 about presenting expanded data from the VIRAGE trial of VCN-01 at a mini oral session during ESMO 2025.

#TOVX Theriva Biologics Provides Response to Unusual Market Action

www.stocktitan.net/news/TOVX/theriva-biolog...

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds Theriva Biologics (NYSE American: TOVX) entered a warrant inducement agreement to accelerate the exercise of existing warrants for up to 7,360,460 shares at a reduced price of $0.54 per share, generating approximately $4.0 million in gross proceeds, with an offer window to raise up to an additional $0.4 million. In return, investors will receive new unregistered warrants to purchase up to 14,720,920 shares at $0.54, exercisable after stockholder approval and expiring five years after the Approval Date. Closing is expected on or about October 17, 2025. Net proceeds are intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners acted as exclusive financial advisor.

#TOVX Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

www.stocktitan.net/news/TOVX/theriva-tm-bio...

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results Theriva Biologics (NYSE American: TOVX) reported significant progress in Q2 2025, highlighted by positive topline results from their VIRAGE Phase 2b trial of VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic cancer. The drug, combined with standard chemotherapy, demonstrated improved overall survival, progression-free survival, and duration of response.The company also presented Phase 1 safety and clinical outcome data for VCN-01 in retinoblastoma at ASCO 2025. Financially, Theriva reported $12.1 million in cash as of June 30, 2025, with runway extending into Q1 2026. General and administrative expenses increased significantly to $11.2 million, while R&D expenses decreased 34% to $2.0 million.

#TOVX Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

www.stocktitan.net/news/TOVX/theriva-tm-bio...

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results Theriva Biologics (NYSE: TOVX) reported significant progress in Q1 2025, highlighted by positive results from the VIRAGE Phase 2b trial of VCN-01 for pancreatic cancer. The trial met primary efficacy and safety endpoints, showing increased overall survival when combined with standard chemotherapy. The company recently completed a public offering raising $7.5 million, extending cash runway into Q1 2026. Financial results show decreased expenses with G&A down 25% to $1.4M and R&D down 14% to $3.0M. Post-offering cash position stands at $14.1 million. The company plans to scale up VCN-01 manufacturing and design a Phase 3 trial for metastatic pancreatic ductal adenocarcinoma (mPDAC). Additionally, data from SYN-004's Phase 1b/2a trial for preventing acute graft-versus-host-disease was presented at ESCMID Global.

#TOVX Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

www.stocktitan.net/news/TOVX/theriva-tm-bio...

Theriva Biologics Announces Pricing of $7.5 Million Public Offering Theriva Biologics (TOVX) has announced the pricing of a public offering to raise approximately $7.5 million through the sale of up to 6,818,180 shares of common stock (or pre-funded warrants) and warrants at a combined price of $1.10 per share. The accompanying warrants will have an exercise price of $1.10 per share, be immediately exercisable, and expire in five years.The offering is expected to close around May 8, 2025. The company plans to use the proceeds for working capital, general corporate purposes, research and development, and manufacturing scale-up. A.G.P./Alliance Global Partners is serving as the sole placement agent for this offering.

#TOVX Theriva Biologics Announces Pricing of $7.5 Million Public Offering

www.stocktitan.net/news/TOVX/theriva-biolog...

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Theriva Biologics (NYSE American: TOVX) has announced the presentation of blinded safety and pharmacokinetic data from their ongoing Phase 1b/2a clinical trial of SYN-004 (ribaxamase). The trial focuses on allogeneic hematopoietic cell transplant recipients for the prevention of acute graft-versus-host-disease (aGVHD).The data will be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria, April 11-15, 2025. Dr. Erik R. Dubberke from Washington University School of Medicine will present the ePoster (E0145) titled 'Safety and tolerability of SYN-004 in allogeneic haematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T)' on April 12, 2025.

#TOVX Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

www.stocktitan.net/news/TOVX/theriva-biolog...

Can Theriva's PDAC Trial Success and FDA Fast Track Save Its Dwindling Cash Position? Phase 2b PDAC trial fully enrolled with Q2 2025 readout, backed by FDA Fast Track status. $11.6M cash extends operations through Q3 2025, supported by new grants.

#TOVX Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

www.stocktitan.net/news/TOVX/theriva-tm-bio...

Theriva Biologics Gets FDA Guidance on VCN-01 Phase 3 Trial Design for Pancreatic Cancer Treatment | TOVX Stock News FDA provides strategic direction for Theriva's VCN-01 pancreatic cancer therapy, recommending standalone Phase 3 trial with gemcitabine/nab-paclitaxel combination.

#TOVX Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

#cancer #news #stocks

www.stocktitan.net/news/TOVX/theriva-tm-bio...